Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 1, 2011, Pages 39-48

  Sessink, Paul J M ^a   Connor, Thomas H ^b   Jorgenson, James A ^c   Tyler, Timothy G ^d  

^a Exposure Control BV   (Netherlands)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c METHODIST HOSPITAL   (United States)

^d Aptium Oncology Inc   (United States)

Author keywords

Antineoplastic agents; closed system drug transfer device; cyclophosphamide; drug preparation; hospital pharmacies; surface contamination

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; IFOSFAMIDE;

ARTICLE; CLOSED SYSTEM DRUG TRANSFER DEVICE; HOSPITAL; INDOOR AIR POLLUTION; PHARMACEUTICS; PHARMACY; PRIORITY JOURNAL; SURFACE CONTAMINATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DRUG COMPOUNDING; ENVIRONMENTAL MONITORING; EQUIPMENT CONTAMINATION; EQUIPMENT DESIGN; FLUOROURACIL; HUMANS; IFOSFAMIDE; OCCUPATIONAL EXPOSURE; PHARMACY SERVICE, HOSPITAL; PROTECTIVE DEVICES; TIME FACTORS; UNITED STATES;

EID: 79952377555     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155210361431     Document Type: Article

References (71)

1. Sessink PJM and Bos RP Drugs hazardous to healthcare workers. Drug Safety 1999 ; 20: 347-359.
2. Acampora A., Castiglia L., Miraglia N., et al. A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 2005 ; 49: 611-618. (Pubitemid 41442686)
3. Connor TH, Anderson RW, Sessink PJM, et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm 1999 ; 56: 1427-1432. (Pubitemid 29331357)
4. Connor TH, Anderson RW, Sessink PJ, et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm 2002 ; 59: 68-72. (Pubitemid 34415055)
5. Crauste-Manciet S., Sessink PJM, Ferrari S., et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005 ; 49: 619-628. (Pubitemid 41444230)
6. Favier B., Rull FM, Bertucat H., et al. Surface and human contamination with 5-fluorouracil in six hospital pharmacies. J Pharm Clin 2001 ; 20: 157-162. (Pubitemid 33051695)
7. Hedmer M., Georgiadi A., Rämme Bremberg E., et al. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 2005 ; 49: 629-637. (Pubitemid 41444231)
8. Kromhout H., Hoek F., Uitterhoeve R., et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 2000 ; 44: 551-560.
9. Leboucher G., Serratrice F., Bertholle V., et al. Evaluation of platinum contamination of a hazardous drug preparation area in a hospital pharmacy. Bull Cancer 2002 ; 89: 949-955. (Pubitemid 36026635)
10. McDevitt JJ, Lees PSJ and McDiarmid MA Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 1993 ; 35: 57-60. (Pubitemid 23018112)
11. Micoli G., Turci R., Arpellini M., et al. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 2001 ; 750: 25-32. (Pubitemid 33648326)
12. Minoia C., Turci R., Sottani C., et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 1998 ; 12: 1485-1493. (Pubitemid 28485973)
13. Ros JJW, Simons KA, Verzijl JM, et al. Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie 1997 ; 13: 168-171.
14. Rubino FM, Floridia L., Pietropaolo AM, et al. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: Applications in occupational hygiene investigations in hospital environments. Med Lav 1999 ; 90: 572-583. (Pubitemid 29438474)
15. Schmaus G., Schierl R. and Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health-Syst Pharm 2002 ; 59: 956-961. (Pubitemid 34522598)
16. Sessink PJM, Anzion RBM, van den Broek PHH, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Week Sci 1992 ; 14: 16-22.
17. Sessink PJM, Friemel NSS, Anzion RBM, et al. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health 1994 ; 65: 401-403.
18. Sessink PJM, Wittenhorst BCJ, Anzion RBM, et al. Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health 1997 ; 52: 240-244.
19. Sessink PJM, Rolf M-AE and Rydèn NS Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm 1999 ; 34: 1311-1317.
20. Sorsa M., Pyy L., Salomaa S., et al. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 1988 ; 204: 465-479. (Pubitemid 18072339)
21. Sottani C., Turci R., Perbellini L., et al. Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Comm Mass Spectrom 1998 ; 12: 1063-1068. (Pubitemid 28370223)
22. Stuart A., Stephens AD, Welch L., et al. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol 2002 ; 9: 186-191. (Pubitemid 34259706)
23. Turci R., Micoli G. and Minoia C. Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatorgraphy: Ultraviolet or tandem mass spectrometry detection. Rapid Comm Mass Spectrom 2000 ; 14: 685-691. (Pubitemid 30218010)
24. Turci R., Sottani C., Spagnoli G., et al. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: A review of analytical methods. J Chromatogr B 2003 ; 789: 169-209. (Pubitemid 36549189)
25. Vandenbroucke J. and Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice 2001 ; 6: 146-152.
26. Wick C., Slawson MH, Jorgenson JA, et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm 2003 ; 60: 2314-2320. (Pubitemid 44712872)
27. Zeedijk M., Greijdanus B., Steenstra FB, et al. Monitoring exposure of cytotoxics on the hospital ward: Measuring surface contamination of four different cytotoxic drugs from one wipe sample. Eur J Hosp Pharm 2005 ; 1: 18-22.
28. Harrison BR, Peters BG and Bing MR Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health-Syst Pharm 2006 ; 63: 1736-1744. (Pubitemid 44413510)
29. Hirst M., Tse S., Mills DG, et al. Occupational exposure to cyclophosphamide. Lancet 1984 ; 1: 186-188. (Pubitemid 14221990)
30. Evelo CTA, Bos RP, Peters JPG, et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 1986 ; 58: 151-155.
31. Sessink PJM, Boer KA, Scheefhals APH, et al. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992 ; 64: 105-112.
32. Sessink PJM, Scholtes MM, Anzion RBM, et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr 1993 ; 616: 333-337.
33. Sessink PJM, Cerna M., Rössner P., et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994 ; 309: 193-199.
34. Sessink PJM, van de Kerkhof MCA, Anzion RBM, et al. Environmental contamination and assessment of exposure to antineoplastic agents by detection of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health 1994 ; 49: 165-169.
35. Ensslin AS, Pethran A., Schierl R., et al. Urinary platinum in hospital personnel occupationally exposed to platinum containing antineoplastic drugs. Int Arch Occup Environ Health 1994 ; 65: 339-342. (Pubitemid 24083182)
36. Ensslin AS, Huber R., Pethran A., et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: Urinary excretion and cytogenetics studies. Int Arch Occup Environ Health 1997 ; 70: 205-208. (Pubitemid 27405894)
37. Nygren O. and Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health 1997 ; 70: 209-214. (Pubitemid 27405895)
38. Turci R., Sottani C. and Minoia C. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Tox Lett 2002 ; 134: 57-64. (Pubitemid 35007286)
39. Pethran A., Schierl R., Hauff K., et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: Monitoring of urinary concentrations. Int Arch Occup Environ Health 2003 ; 76: 5-10. (Pubitemid 36740714)
40. Schreiber C., Radon K., Pethran A., et al. Uptake of antineoplastic agents in pharmacy personnel. Part II: Study of work-related risk factors. Int Arch Occup Environ Health 2003 ; 76: 11-16. (Pubitemid 36740715)
41. Sessink PJM, Kroese ED, van Kranen HJ, et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 1995 ; 67: 317-323.
42. Sotaniemi EA, Sutinen S., Arrano AJ, et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983 ; 214: 181-189. (Pubitemid 14230855)
43. Hemminki K., Kyyronen P. and Lindbohm M. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health 1985 ; 39: 141-147. (Pubitemid 15050152)
44. Selevan SG, Lindbohm M., Hornung RW, et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Eng J Med 1985 ; 313: 1173-1178. (Pubitemid 16205333)
45. Valanis BG, Hertzberg V. and Shortridge L. Antineoplastic drugs. Handle with care. AAOHN J 1987 ; 35: 487-492. (Pubitemid 17164541)
46. Skov T., Lynge E., Maarup B., et al. Risks for physicians handling antineoplastic drugs (letter). Lancet 1990 ; 2: 1446.
47. Skov T., Maarup B., Olsen J., et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992 ; 49: 855-861.
48. Valanis BG, Vollmer WM, Labuhn KT, et al. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993 ; 50: 455-462. (Pubitemid 23083709)
49. Hansen J. and Olsen JH Cancer morbidity among Danish female pharmacy technicians. Scan J Work Environ Health 1994 ; 20: 22-26.
50. Valanis BG, Vollmer WM, Labuhn KT, et al. Occupational exposure to antineoplastic agents and self reported infertility among nurses and pharmacists. J Occup Environ Med 1997 ; 39: 574-580.
51. Valanis B., Vollmer W. and Steele P. Occupational exposure to antineoplastic agents: Self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999 ; 41: 632-638. (Pubitemid 29382927)
52. Peelen S., Roeleveld N., Heederik D., et al. Toxic effects on reproduction in hospital personnel. Dutch Ministry of Social Affairs and Employment. ISBN 9057492555 (in Dutch).
53. McDonald AD, McDonald JC, Armstrong B., et al. Congenital defects and work in pregnancy. Br J Ind Med 1988 ; 45: 581-588.
54. Stucker I., Caillard JF, Collin R., et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990 ; 16: 102-107. (Pubitemid 20148988)
55. Valanis BG, Vollmer WM, Labuhn KT, et al. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs 1993 ; 16: 288-295. (Pubitemid 23261127)
56. Saurel-Cubizolles MJ, Job-Spira N. and Estryn-Behar M. Ectopic pregnancy and occupational exposure to antinoplastic drugs. Lancet 1993 ; 341: 1169-1171. (Pubitemid 23137111)
57. McAbee RR, Gallucci BJ and Checkoway H. Adverse reproductive outcomes and occupational exposures among nurses: An investigation of multiple hazardous exposures. AAOHN J 1993 ; 41: 110-119. (Pubitemid 23119366)
58. Levin LI, Holly EA and Seward JP Bladder cancer in a 39-year old female pharmacist. J Natl Cancer Inst 1993 ; 85: 1089-1091. (Pubitemid 23199192)
59. Gunnarsdottir HK, Aspelund T., Karlsson T., et al. Occupational risk factors for breast cancer among nurses. Int J Occup Environ Health 1997 ; 3: 254-258. (Pubitemid 127816922)
60. Bouyer J., Saurel-Cubizolles MJ, Grenier C., et al. Ectopic pregnancy and occupational exposure of hospital personnel. Scand J Work Environ Health 1998 ; 24: 98-103. (Pubitemid 28233861)
61. Lorente C., Cordier S., Bergeret A., et al. Maternal occupational risk factors for oral clefts. Occupational exposure and congenital malformation working group. Scand J Work Environ Health 2000 ; 26: 137-145.
62. Mader RM, Rizovski B., Steger GG, et al. Exposure of oncology nurses to methotrexate in the treatment of osteosarcoma. Arch Environ Health 1996 ; 51: 310-314. (Pubitemid 26262466)
63. American Society of Hospital Pharmacists.. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990 ; 47: 1033-1049.
64. Niosh Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No 2004 -165.
65. American Society of Health-System Pharmacists.. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm 2006 ; 63: 1172-1193.
66. Spivey S. and Connor TH Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system. Hosp Pharm 2003 ; 38: 135-139. (Pubitemid 36232308)
67. American Society of Health-System Pharmacists.. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990 ; 47: 1033-1049.
68. Controlling occupational exposure to hazardous drugs. OSHA technical manual (OSHA instruction CPL 2-2.20B CH-4). Chap 21. Washington, DC: Occupational Safety and Health Administration, 1995.
69. Sessink PJM Monitoring of occupational exposure to antineoplastic agents 1996. Thesis, The University Nijmegen, The Netherlands.
70. Connor TH, Sessink PJM, Harrison BR, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies. Am J Health-Syst Pharm 2005 ; 62: 475-484. (Pubitemid 40332257)
71. Nyman H., Jorgenson J. and Slawson MH Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm 2007 ; 42: 219-225. (Pubitemid 46632294)